Modern clinical research on LSD
Open accessAbstract
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT 2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left amygdala reactivity to fearful faces, and enhanced emotional empathy. LSD increased the emotional response to music and the meaning of music. LSD acutely produced deficits in sensorimotor gating, similar to observations in schizophrenia. LSD had weak autonomic stimulant effects and elevated plasma cortisol, prolactin, and oxytocin levels. Resting-state functional magnetic resonance studies showed that LSD acutely reduced the integrity of functional brain networks and increased connectivity between networks that normally are more dissociated. LSD increased functional thalamocortical connectivity and functional connectivity of the primary visual cortex with other brain areas. The latter effect was correlated with subjective hallucinations. LSD acutely induced global increases in brain entropy that were associated with greater trait openness 14 days later. In patients with anxiety associated with life-threatening disease, anxiety was reduced for 2 months after two doses of LSD. In medical settings, no complications of LSD administration were observed. These data should contribute to further investigations of the therapeutic potential of LSD in psychiatry.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both LSD and psilocybin are agonists at 5-HT1A, 5-HT2A and 5-HT2C receptors with varying affinities, whereby full or partial agonism at the 5-HT2A receptor is likely to be the necessary site of action for eliciting an altered state of consciousness including prosocial and pro-cognitive effects.
“Both drugs are agonists at 5-HT 1A , 5-HT 2A and 5-HT 2C receptors with varying affinities, whereby the full or partial agonism at the 5-HT 2A receptor is likely to be the necessary site of action for eliciting an altered state consciousness including prosocial and pro-cognitive effects.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Liechti, 2017
5-HT2A receptor signalling has also been implicated in processes of neuroplasticity, such as neurogenesis, neurodevelopment, learning, including extinction learning, cognitive flexibility and enhanced environmental sensitivity.
“Importantly, 5-HT 2A receptor signalling has also been implicated in processes of neuroplasticity, such as neurogenesis, neurodevelopment, learning, including extinction learning, cognitive flexibility and enhanced environmental sensitivity (Liechti, 2017).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Liechti, 2017
Classic serotonergic psychedelics LSD and psilocybin have been shown to alter the state of consciousness in a way that is thought to be helpful during psychotherapeutic interventions.
“For example, the classic serotonergic psychedelics LSD and psilocybin (magic mushrooms) have been shown to alter the state of consciousness in a way that is thought to be helpful during psychotherapeutic interventions (Liechti, 2017).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Liechti, 2017
MDMA has demonstrated anxiolytic effects when administered to patients suffering from a life-threatening illness.
“For instance, MDMA has demonstrated anxiolytic effects when administered to patients suffering from a life-threatening illness (Liechti, 2017)”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Liechti, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 5× · see citing works
“Recent trials investigated psilocybin in patients with alcohol and nicotine use disorder Neuropsychopharmacology (Bogenschutz et al, 2015; Johnson et al, 2014), major depression, and anxiety (Carhart-Harris et al, 2016a; Griffiths et al, 2016; Grob et al, 2011; Ross et al, 2016).”
BackgroundInfluentialNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · see citing works
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · see citing works
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · see citing works
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · see citing works
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · see citing works
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 11× · see citing works
“Neuropsychopharmacology intravenous dose of 75 μg LSD that was used in the London studies.”
BackgroundInfluentialPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · see citing works
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works
Pilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2× · see citing works
“Recent trials investigated psilocybin in patients with alcohol and nicotine use disorder Neuropsychopharmacology (Bogenschutz et al, 2015; Johnson et al, 2014), major depression, and anxiety (Carhart-Harris et al, 2016a; Griffiths et al, 2016; Grob et al, 2011; Ross et al, 2016).”
BackgroundMethodMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · see citing works
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · see citing works
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · see citing works
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · see citing works
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 1× · see citing works
“In controlled nontherapeutic research settings, psilocybin did not produce HPPD or flashbacks (Studerus et al, 2011).”
BackgroundIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · see citing works
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488 · see citing works
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · see citing works
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2063-13.2013 · Cited by 465 · see citing works
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456 · see citing works
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · see citing works
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453 · see citing works
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · see citing works
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · see citing works
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427 · see citing works
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 409 · see citing works
Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402 · see citing works
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · see citing works
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 373 · see citing works
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 360 · see citing works
MDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356 · see citing works
Self-citationKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323 · see citing works
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · see citing works
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · see citing works
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 1× · see citing works
“It has been proposed that the PET study findings of hyperfrontality reflect the increased neuronal firing activity while fMRI BOLD measures correlate with cortical oscillatory activity (Halberstadt, 2015).”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306 · see citing works
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303 · see citing works
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298 · see citing works
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · see citing works
Dose-Response Study of N,N-Dimethyltryptamine in Humans
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291 · see citing works
Phenomenology, Structure, and Dynamic of Psychedelic States
Preller, K. H., & Vollenweider, F. X. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_459 · Cited by 282 · see citing works
Roseman, L., Leech, R., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00204 · Cited by 274 · see citing works
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256 · see citing works
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247 · see citing works
Self-citationThe behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 226 · see citing works
The experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220 · see citing works
Rickli, A., Luethi, D., Reinisch, J., Buchy, D., Hoener, M. C., & Liechti, M. E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.034 · Cited by 215 · see citing works
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198 · see citing works
Self-citationGouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 194 · see citing works
Psychedelics in the treatment of unipolar mood disorders: a systematic review
Rucker, J., Jelen, L. A., Flynn, S. K., Frowde, K., & Young, A. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116679368 · Cited by 185 · see citing works
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Krähenmann, R., Pokorný, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E., & Vollenweider, F. X. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4610-0 · Cited by 177 · see citing works
LSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 161 · see citing works
Kometer, M., Pokorny, T., Seifritz, E., & Volleinweider, F. X. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4026-7 · Cited by 157 · see citing works
(1969) · PubMed · Cited by 150 · see citing works
Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations
Müller, F., Lenz, C., Dolder, P. C., Lang, U. E., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12818 · Cited by 137 · see citing works
Halpern, J. H., Lerner, A. G., & Passie, T. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_457 · Cited by 133 · cited 1× · see citing works
“However, the prevalence and relevance of HPPD is unclear and needs to be studied (Halpern et al, 2016).”
BackgroundPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0513-9 · Cited by 133 · see citing works
LSD modulates music-induced imagery via changes in parahippocampal connectivity
Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orbán, C., Lorenz, R., Barrett, F. S., Bolstridge, M., Williams, T., Williams, L., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.018 · Cited by 131 · see citing works
Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects
Strajhar, P., Schmid, Y., Liakoni, E., Dolder, P. C., Rentsch, K., Kratschmar, D. V., Odermatt, A., & Liechti, M. E. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12374 · Cited by 129 · see citing works
Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Müller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 128 · see citing works
Hysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001132 · Cited by 126 · see citing works
Belleville, R. E., Fraser, H. F., Isbell, H., LOGAN, C. R., & Wikler, A. (1956) · PubMed · Cited by 126 · see citing works
Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01609.x · Cited by 125 · see citing works
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124 · see citing works
Comparison of psilocin with psilocybin, mescaline and LSD-25
Wolbach, A. B., Miner, E. J., & Isbell, H. (1962) · Psychopharmacology · doi:10.1007/bf00412109 · Cited by 123 · see citing works
Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D., & Carhart-Harris, R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628430 · Cited by 118 · see citing works
Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K., & Liechti, M. E. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv072 · Cited by 112 · see citing works
Studies on Lysergic Acid Diethylamide (LSD-25)
Isbell, H. (1956) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1956.02330290012002 · Cited by 112 · see citing works
Simmler, L. D., Buchy, D., Chaboz, S., Hoener, M. C., & Liechti, M. E. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229765 · Cited by 108 · see citing works
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler, E. A. D., Gottschalk, C. H., Weil, M. J., Shapiro, R. E., Wright, D. A., & Sewell, R. A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1107664 · Cited by 103 · see citing works
Baggott, M. J., Coyle, J., Erowid, E., Erowid, F., & Robertson, L. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.006 · Cited by 92 · see citing works
Kuypers, K. P., Dolder, P. C., Ramaekers, J. G., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699617 · Cited by 89 · see citing works
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82 · see citing works
Hollister, L. E., & Hartman, A. M. (1962) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(62)80024-8 · Cited by 73 · see citing works
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
Halberstadt, A. L., & Geyer, M. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1718-x · Cited by 72 · see citing works
Marona‐Lewicka, D., & Nichols, D. E. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.001 · Cited by 64 · see citing works
Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orbán, C., McGonigle, J., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23224 · Cited by 59 · see citing works
Seibert, J., Hysek, C. M., Penno, C. A., Schmid, Y., Kratschmar, D. V., Liechti, M. E., & Odermatt, A. (2014) · Neuroendocrinology · doi:10.1159/000364879 · Cited by 52 · see citing works
A placebo-controlled investigation of synaesthesia-like experiences under LSD
Terhune, D. B., Luke, D. P., Kaelen, M., Bolstridge, M., Feilding, A., Nutt, D., Carhart-Harris, R. L., & Ward, J. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.04.005 · Cited by 45 · see citing works
Dolder, P. C., Liechti, M. E., & RENTSCH, K. M. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8388-1 · Cited by 44 · see citing works
Steuer, A. E., Poetzsch, M., Stock, L., Eisenbeiss, L., Schmid, Y., Liechti, M. E., & Kræmer, T. (2016) · Drug Testing and Analysis · doi:10.1002/dta.2042 · Cited by 41 · see citing works
The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making
Preller, K. H., Pokorny, T., Krähenmann, R., Dziobek, I., Stämpfli, P., & Vollenweider, F. X. (2015) · European Psychiatry · doi:10.1016/s0924-9338(15)30017-1 · Cited by 20 · see citing works
Nutt, D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675754 · Cited by 19 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Schmidt A, Müller F, Lenz C, Dolder PC, Schmid Y, Zanchi D et al (2017). Acute LSD effects on response inhibition neuronal networks in healthy subjects. (submitted and under review).
- Sheehan DV (1972). Review of the use of LSD for the patient near death. Psychiatric Forum 3: 21–23.
Cited by
Sorted by citations
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649 · see citing works
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 327 · see citing works
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269 · see citing works
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262 · see citing works
Self-citationLong-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257 · see citing works
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247 · see citing works
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · see citing works
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232 · see citing works
SANTOS, R. G. D., Bouso, J. C., Alcázar‐Córcoles, M. Á., & Hallak, J. E. C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1511424 · Cited by 228 · see citing works
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226 · see citing works
Self-citationKuypers, K., Ng, L., Erritzoe, D., Knudsen, G., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 188 · see citing works
Altered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174 · see citing works
LSD alters dynamic integration and segregation in the human brain
Luppi, A. I., Carhart-Harris, R. L., Roseman, L., Pappas, I., Menon, D. K., & Stamatakis, E. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117653 · Cited by 159 · see citing works
Yanakieva, S., Polychroni, N., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5119-x · Cited by 167 · see citing works
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · see citing works
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 146 · see citing works
Serotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138 · see citing works
Motives and Side-Effects of Microdosing With Psychedelics Among Users
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz029 · Cited by 126 · see citing works
Psychedelic microdosing benefits and challenges: an empirical codebook
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0308-4 · Cited by 124 · see citing works
Microdosing psychedelics: Motivations, subjective effects and harm reduction
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., & Klein, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.11.008 · Cited by 121 · see citing works
Trends in LSD use among US adults: 2015–2018
Yockey, R. A., Vidourek, R. A., & King, K. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108071 · Cited by 111 · see citing works
Varley, T. F., Carhart-Harris, R. L., Roseman, L., Menon, D. K., & Stamatakis, E. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117049 · Cited by 88 · see citing works
Chi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95 · see citing works
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94 · see citing works
Dose–response relationships of psilocybin-induced subjective experiences in humans
Hirschfeld, T., & Schmidt, T. T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121992676 · Cited by 93 · see citing works
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Ramaekers, J. G., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. C. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120940937 · Cited by 92 · see citing works
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 91 · see citing works
Chemical warfare agents. Classes and targets
Schwenk, M. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.11.040 · Cited by 90 · see citing works
Nichols, D. E., & Grob, C. S. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.01.006 · Cited by 89 · see citing works
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88 · see citing works
Michaiel, A. M., Parker, P. R. L., & Niell, C. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.104 · Cited by 82 · see citing works
The therapeutic potential of microdosing psychedelics in depression
Kuypers, K. P. C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950567 · Cited by 85 · see citing works
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 89 · see citing works
Dark Classics in Chemical Neuroscience: Mescaline
Cassels, B. K., & Sáez-Briones, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00215 · Cited by 85 · see citing works
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020) · Chronic Stress · doi:10.1177/2470547020939564 · Cited by 83 · see citing works
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N., Thomas, C., & Hutson, P. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 67 · see citing works
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77 · see citing works
The role of the methoxy group in approved drugs
Chiodi, D., & Ishihara, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116364 · Cited by 80 · see citing works
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Anghel, D.-M. C., Nițescu, G., Tiron, A., Guțu, C., & Baconi, D. (2023) · Molecules · doi:10.3390/molecules28134969 · Cited by 85 · see citing works
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Holze, F., Duthaler, U., Vizeli, P., Müller, F., Borgwardt, S., & Liechti, M. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13918 · Cited by 73 · see citing works
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., Wallach, J. V., & Halberstadt, A. L. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2613 · Cited by 72 · see citing works
Luethi, D., & Liechti, M. E. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy047 · Cited by 70 · see citing works
Classics in Chemical Neuroscience: Amitriptyline
McClure, E. W., & Daniels, R. N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00467 · Cited by 70 · see citing works
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 74 · see citing works
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65 · see citing works
Holze, F., Liechti, M. E., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Duthaler, U., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2057 · Cited by 65 · see citing works
van Mulukom, V., Patterson, R. E., & van Elk, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05568-y · Cited by 62 · see citing works
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 66 · see citing works
Elsey, J. W. B. (2017) · Drug Science Policy and Law · doi:10.1177/2050324517723232 · Cited by 57 · see citing works
Vizeli, P., Straumann, I., Holze, F., Schmid, Y., Dolder, P. C., & Liechti, M. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-90343-y · Cited by 55 · see citing works
Metabolism of lysergic acid diethylamide (LSD): an update
Libânio Osório Marta, R. F. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1638931 · Cited by 54 · see citing works
Wagmann, L., Richter, L. H. J., Kehl, T., Wack, F., Bergstrand, M. P., Brandt, S. D., Stratford, A., Maurer, H. H., & Meyer, M. R. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1558-9 · Cited by 53 · see citing works
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51 · see citing works
Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action
Canal, C. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_107 · Cited by 48 · see citing works
Rudin, D., Liechti, M. E., & Luethi, D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113778 · Cited by 48 · see citing works
Kopra, E. I., Ferris, J., Rucker, J., McClure, B., Young, A., Copeland, C., & Winstock, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221099650 · Cited by 42 · see citing works
Luethi, D., Hoener, M. C., Krähenbühl, S., Liechti, M. E., & Duthaler, U. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.013 · Cited by 46 · see citing works
Straumann, I., Ley, L., Holze, F., Becker, A., Klaiber, A., Wey, K., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01609-0 · Cited by 44 · see citing works
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
Robison, R. J., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Jemison, J., Karas, S. M., Karlin, D. R., Solomon, T. M., et al. (2025) · JAMA · doi:10.1001/jama.2025.13481 · Cited by 44 · see citing works
Plazas, E., & Faraone, N. (2023) · Biomedicines · doi:10.3390/biomedicines11020461 · Cited by 41 · see citing works
Yu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 42 · see citing works
Volgin, A. D., Yakovlev, O. A., Demin, K. A., Alekseeva, P. A., Kyzar, E. J., Collins, C. J., Nichols, D. E., & Kalueff, A. V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00433 · Cited by 38 · see citing works
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39 · see citing works
The Treatment of Substance Use Disorders: Recent Developments and New Perspectives
Rosenthal, A., Ebrahimi, C., Wedemeyer, F., Romanczuk‐Seiferth, N., & Beck, A. (2022) · Neuropsychobiology · doi:10.1159/000525268 · Cited by 40 · see citing works
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Ornelas, I. M., da Silva, F. A. C., Wießner, I., Marcos, E., de Araújo, D. B., Goto‐Silva, L., Nascimento, J. M., Silva, S. R. B., Costa, M., Falchi-Carvalho, M., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114148 · Cited by 36 · see citing works
Müller, F., Liechti, M. E., Lang, U. E., & Borgwardt, S. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.004 · Cited by 31 · see citing works
Prodrugs of New Psychoactive Substances (NPS): A New Challenge
Elliott, S. P., Holdbrook, T., & Brandt, S. D. (2020) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14268 · Cited by 33 · see citing works
Biosynthesis, total synthesis, and biological profiles of Ergot alkaloids
Tasker, N. R., & Wipf, P. (2020) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/bs.alkal.2020.08.001 · Cited by 33 · see citing works
LSD and ketanserin and their impact on the human autonomic nervous system
Olbrich, S., Preller, K. H., & Vollenweider, F. X. (2021) · Psychophysiology · doi:10.1111/psyp.13822 · Cited by 31 · see citing works
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1415755 · Cited by 31 · see citing works
de Abreu, M. S., Giacomini, A. C. V. V., Demin, K. A., Galstyan, D. S., Zabegalov, K. N., Kolesnikova, T. O., Amstislavskaya, T. G., Strekalova, T. V., Petersen, E. V., & Kalueff, A. V. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173205 · Cited by 31 · see citing works
Psychedelics and hypnosis: Commonalities and therapeutic implications
Lemercier, C. E., & Terhune, D. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780714 · Cited by 26 · see citing works
Sapienza, J., Bosia, M., Spangaro, M., Martini, F., Agostoni, G., Cuoco, F., Cocchi, F., & Cavallaro, R. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01721-5 · Cited by 28 · see citing works
Grumann, C., Henkel, K., Brandt, S. D., Stratford, A., Passie, T., & Auwärter, V. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2821 · Cited by 26 · see citing works
Graph neural fields: A framework for spatiotemporal dynamical models on the human connectome
Aqil, M., Atasoy, S., Kringelbach, M. L., & Hindriks, R. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008310 · Cited by 27 · see citing works
Suzuki, K., Seth, A. K., & Schwartzman, D. J. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1159821 · Cited by 25 · see citing works
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., Ribeiro, S. T. G., Mota, N. B., de Araújo, D. B., & Tófoli, L. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06006-3 · Cited by 23 · see citing works
Henríquez‐Hernández, L. A., Rojas‐Hernández, J., Hernández, D. J. Q., & Borkel, L. F. (2023) · Toxics · doi:10.3390/toxics11020148 · Cited by 23 · see citing works
Family, N., Hendricks, P. S., Williams, L. T. J., Luke, D. P., Maillet, É. L., Maillet, É. L., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069103 · Cited by 22 · see citing works
Substances of abuse and the blood brain barrier: Interactions with physical exercise
Małkiewicz, M. A., Małecki, A., Toborek, M. J., Szarmach, A., & Winklewski, P. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.026 · Cited by 20 · see citing works
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 21 · see citing works
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 23 · see citing works
Pharmacologic Similarities and Differences Among Hallucinogens
Waters, K. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1917 · Cited by 19 · see citing works
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 21 · see citing works
Yockey, R. A., King, K. A., & Vidourek, R. A. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.014 · Cited by 19 · see citing works
Asymmetry in Psychoactive Research: A Bibliometric Study on 15 Psychoactive Drugs
Lebrero-Tatay, J., Sebag, A., & Ezquerra-Romano, I. (2022) · Journal of Drug Issues · doi:10.1177/00220426211068439 · Cited by 18 · see citing works
Neurotoxicology Syndromes Associated with Drugs of Abuse
Caplan, R. A., Zuflacht, J. P., Barash, J. A., & Fehnel, C. R. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.08.005 · Cited by 18 · see citing works
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 19 · see citing works
Domenico, C. M., Haggerty, D. C., Mou, X., & Ji, D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109714 · Cited by 17 · see citing works
Kolaczynska, K. E., Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794254 · Cited by 15 · see citing works
The versatile binding landscape of the TAAR1 pocket for LSD and other antipsychotic drug molecules
Jiang, K., Zheng, Y. Y., Zeng, L., Wang, L., Li, F., Pu, J., Lu, Y., Zhao, S., & Xu, F. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114505 · Cited by 15 · see citing works
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 15 · see citing works
Lumpy Skin Disease: Insights into Molecular Pathogenesis and Control Strategies
Haider, A., Abbas, Z., Taqveem, A., Ali, A. S., Khurshid, M., Naggar, R. F. E., Rohaim, M. A., & Munir, M. (2024) · Veterinary Sciences · doi:10.3390/vetsci11110561 · Cited by 15 · see citing works
Askariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111461 · Cited by 14 · see citing works
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 14 · see citing works
Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Fonseka, L. N., & Woo, B. K. P. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.182 · Cited by 13 · see citing works
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Madrid-Gambín, F., Fabregat‐Safont, D., Gomez‐Gómez, À., Olesti, E., Mason, N. L., Ramaekers, J. G., & Pozo, Ó. J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115775 · Cited by 14 · see citing works
Effects of hallucinogenic drugs on the human heart
Neumann, J., Dhein, S., Kirchhefer, U., Hofmann, B., & Gergs, U. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1334218 · Cited by 16 · see citing works
Ghaw, A., Chunduri, A., Chang, A., Ortiz, R. J., Kozlowska, M., Kulkarni, P. P., & Ferris, C. F. (2024) · Brain Communications · doi:10.1093/braincomms/fcae194 · Cited by 13 · see citing works
- Authors
- Liechti, M. E.
- Affiliations
- University of Basel (CH)
- Corresponding author
- Liechti, Matthias E
- ORCID
- Liechti, Matthias E
- Venue
- Neuropsychopharmacology
- Published
- 2017-04-27
- Volume
- 42
- Issue
- 11
- Pages
- 2114-2127
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC5603820
- OpenAlex
- W2607844825
- Cited by
- 236
- References
- 86
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 26 · 2023: 42 · 2022: 22 · 2021: 34 · 2020: 33 · 2019: 17 · 2018: 14 · 2017: 5
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (170249, 320030)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- lysergic acid diethylamide, LSD, 5-HT2A receptor, synesthesia, derealization, depersonalization, mystical experience, face recognition (cognition), amygdala, affective empathy, music perception, sensorimotor gating, autonomic effects, cortisol, prolactin, oxytocin, resting-state functional connectivity, thalamocortical connections, brain entropy, anxiety, psychedelic therapy
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, History, 20th Century, History, 21st Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
